Neuren Pharmaceuticals Limited (OTCMKTS:NURPF – Get Free Report) traded up 10.1% on Friday . The stock traded as high as C$12.91 and last traded at C$12.91. 190 shares traded hands during trading, a decline of 84% from the average session volume of 1,169 shares. The stock had previously closed at C$11.73.
Neuren Pharmaceuticals Stock Performance
The company has a 50-day moving average of C$13.03 and a two-hundred day moving average of C$10.61.
About Neuren Pharmaceuticals
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide), which has been registered to treat Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome.
Featured Articles
- Five stocks we like better than Neuren Pharmaceuticals
- The How And Why of Investing in Oil Stocks
- OpenAI’s Restructuring Sets up What Could Be the Biggest IPO Ever
- How to Use the MarketBeat Stock Screener
- 2 Rare Earth Stocks the U.S. Government Doesn’t Want to Fail
- How to find penny stocks to invest and trade
- CrowdStrike Partners With CoreWeave But Investors Sell the News
Receive News & Ratings for Neuren Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuren Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
